MY130725A - Composition and method for treating allergic diseases - Google Patents

Composition and method for treating allergic diseases

Info

Publication number
MY130725A
MY130725A MYPI99004311A MYPI9904311A MY130725A MY 130725 A MY130725 A MY 130725A MY PI99004311 A MYPI99004311 A MY PI99004311A MY PI9904311 A MYPI9904311 A MY PI9904311A MY 130725 A MY130725 A MY 130725A
Authority
MY
Malaysia
Prior art keywords
composition
allergic diseases
treating allergic
effective amount
therapeutically effective
Prior art date
Application number
MYPI99004311A
Inventor
Robert G Aslanian
John J Piwinski
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MY130725A publication Critical patent/MY130725A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

THE PRESENT INVENTION IS DIRECTED TOWARDS A PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF ALEERGIC RHINITIS, ASTHMA AND RELATED DISORDERS. IN ONE EMBODIMENT, THE COMPOSITION COMPRISES, IN COMBINATION, A THERAPEUTICALLY EFFECTIVE AMOUNT OF AT LEAST ONE NEUROKININ ANTAGONIST, A THERAPEUTICALLY EFFECTIVE AMOUNT OF AT LEAST ONE H3 ANTAGONIST AND A THERAPEUTICALLY EFFECTIVE AMOUNT OF AT LEAST ONE H1 ANTAGONIST.
MYPI99004311A 1998-10-09 1999-10-06 Composition and method for treating allergic diseases MY130725A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16960898A 1998-10-09 1998-10-09

Publications (1)

Publication Number Publication Date
MY130725A true MY130725A (en) 2007-07-31

Family

ID=22616405

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI99004311A MY130725A (en) 1998-10-09 1999-10-06 Composition and method for treating allergic diseases

Country Status (10)

Country Link
EP (1) EP1117405A2 (en)
JP (1) JP2002527381A (en)
CN (1) CN1329490A (en)
AR (1) AR020740A1 (en)
AU (1) AU6252699A (en)
CA (1) CA2346227A1 (en)
CO (1) CO5140078A1 (en)
MY (1) MY130725A (en)
PE (1) PE20001097A1 (en)
WO (1) WO2000021512A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020324A1 (en) * 2000-10-06 2002-06-18 Boehringer Ingelheim Int NEW PHARMACEUTICAL COMPOSITIONS CONTAINING EPINASTIN AND PSEUDOEPHEDRINE
PE20020507A1 (en) * 2000-10-17 2002-06-25 Schering Corp NON-IMIDAZOLE COMPOUNDS AS ANTAGONISTS OF THE HISTAMINE H3 RECEPTOR
US20040198743A1 (en) * 2003-01-31 2004-10-07 Schering Corporation Methods for treating allergic skin and allergic ocular conditions using combinations of histamine receptor antagonists
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
WO2009142772A2 (en) 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
DE102012102417A1 (en) 2012-03-21 2013-09-26 Balluff Gmbh identification system
EP3520803A1 (en) * 2018-01-31 2019-08-07 Zarodex Therapeutics Limited Novel uses
CN116496205A (en) * 2022-05-06 2023-07-28 成都施贝康生物医药科技有限公司 Cardustatin salt and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310066D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Alkyl substituted heterocycles
NZ292683A (en) * 1994-08-25 1998-07-28 Merrell Pharma Inc Piperidine derivatives
US5688960A (en) * 1995-05-02 1997-11-18 Schering Corporation Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
CA2263163A1 (en) * 1996-08-16 1998-02-19 Schering Corporation Treatment of upper airway allergic responses with a combination of histamine receptor antagonists

Also Published As

Publication number Publication date
JP2002527381A (en) 2002-08-27
WO2000021512A3 (en) 2000-07-06
EP1117405A2 (en) 2001-07-25
CO5140078A1 (en) 2002-03-22
WO2000021512A2 (en) 2000-04-20
AR020740A1 (en) 2002-05-29
AU6252699A (en) 2000-05-01
CA2346227A1 (en) 2000-04-20
PE20001097A1 (en) 2000-10-31
CN1329490A (en) 2002-01-02

Similar Documents

Publication Publication Date Title
CY1115589T1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF CENTRAL Nervous System Disorders Including a Nicotinic Enhancer
BR0307050A (en) Compound, pharmaceutical composition, methods for treating prostaglandin d2 mediated diseases, for treating nasal congestion, for treating allergic asthma, and for treating allergic rhinitis, pharmaceutically acceptable salt, and use of a compound or salt
SE9803710D0 (en) Use of certain drugs for treating nerve root injury
WO2005063297A3 (en) Melatonin combination therapy for improving sleep quality
MXPA03011515A (en) Novel pharmaceutical compositions based on anticholinergic agents, corticosteroids and betamimetic agents.
MY134110A (en) Combinations of reboxetine and neuroleptic agents
EP1007556A4 (en) Troponin subunits and fragments useful as angiogenesis inhibitors
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
HRP20050224B1 (en) Novel combination of glucocorticoid and pde-4-inhibitors for treating respiratory diseases, allergic diseases, asthma and copd
MXPA06000705A (en) Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders.
NZ271363A (en) Use of antiglucocorticoid steroids to treat anxiety disorders
MY130725A (en) Composition and method for treating allergic diseases
SE9603725D0 (en) New teatment
WO2000012045A3 (en) Method for treating neurodegenerative disorders
BG103687A (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative processes and conditions related to the central nervous system
EE200100553A (en) Use of saredutant and pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment or prevention of mood disorders, adaptive disorders, or mixed anxiety depressive disorders.
WO2003015690A3 (en) Method for treating primary insomnia
MXPA02011921A (en) Naaladase inhibitors for treating retinal disorders and glaucoma.
DZ3225A1 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF LUNG DISEASES
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
HUP0103712A2 (en) Salts of paroxetine, process for their preparation and their pharmaceutical use
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
AR020741A1 (en) COMPOSITION AND METHOD TO TREAT ALLERGIC DISEASES
HUP0101748A3 (en) Use of reboxetine for producing pharmaceutical compositions suitable for treating nervous disorders
HK1059391A1 (en) Use of quetiapine for the treatment of cocaine dependence